TELOMIR PHARMA Reported Earnings

TELOMIR PHARMA (TELO) reported a loss of $0.79 per share on revenue of $0.00 million for the . .

Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE.